Biological Triggers of Depression in Pregnancy
Status: | Completed |
---|---|
Conditions: | Depression, Depression, Psychiatric |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 6/30/2018 |
Start Date: | October 23, 2014 |
End Date: | February 28, 2017 |
The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality
The goal of the study is to define and measure biological processes that contribute to the
underlying pathophysiologic process of peri-partum depression to be used for identifying
those at risk for developing it. This knowledge may also generate novel drug targets for
peripartum depression that may be applicable to other types of depression.
underlying pathophysiologic process of peri-partum depression to be used for identifying
those at risk for developing it. This knowledge may also generate novel drug targets for
peripartum depression that may be applicable to other types of depression.
This study analyses the role of inflammation and metabolites of inflammation in perinatal
depression. Psychiatric assessments of depression and suicidality will be compared to blood
levels of two metabolites of inflammation, quinolinic acid (QUIN) and picolinic acid (PIC),
that might regulate nerve cell communication. The levels of these metabolites are regulated
by kynurenine pathway enzymes.
Psychiatric symptoms, inflammatory cytokines and levels of the metabolites will be measured
throughout pregnancy. Additionally, the investigators are gathering placentas at delivery and
determining the degree of inflammation in the tissue in the investigators' laboratory.
Inflammatory biomarkers, antibody titers, and key kynurenine pathway enzymes and metabolites
from pre- and post partum women, placenta, and cord blood will be measured.
depression. Psychiatric assessments of depression and suicidality will be compared to blood
levels of two metabolites of inflammation, quinolinic acid (QUIN) and picolinic acid (PIC),
that might regulate nerve cell communication. The levels of these metabolites are regulated
by kynurenine pathway enzymes.
Psychiatric symptoms, inflammatory cytokines and levels of the metabolites will be measured
throughout pregnancy. Additionally, the investigators are gathering placentas at delivery and
determining the degree of inflammation in the tissue in the investigators' laboratory.
Inflammatory biomarkers, antibody titers, and key kynurenine pathway enzymes and metabolites
from pre- and post partum women, placenta, and cord blood will be measured.
Inclusion Criteria
Pre-partum cohort:
- All races and national origins of pregnant females.
- Age 18 and older.
- English speaking.
- Able to give informed consent.
- Able to comply with study procedures.
Exclusion Criteria
Pre-partum cohort:
- Non-pregnant females
- Patients with psychotic symptoms and/or severe cognitive impairment that interfere
with their ability to give informed consent or to complete study assessments.
- Patients that cannot read and write in English as research measures used have only
been validated in English speaking populations.
- Patients that have blood-borne chronic infections including hepatitis B, C, or HIV as
established at routine pregnancy blood screens; they will be excluded as the
laboratory facilities do not approve processing of their tissue for safety reasons.
- Patients who have any schizophrenia spectrum disorder or bipolar disorder type 1
(based on self report and SCID interview); these patients will be excluded as the
neurobiology of these disorders are different from peripartum depression.
- Patients who report ongoing substance abuse or dependence (in the past 3 months).
Inclusion criteria
Post-partum cohort:
- All races and national origins of females who delivered a child vaginally or by
caesarian section up to 6 months prior to enrollment.
- Age 18 and older.
- Edinburgh Perinatal Depression Rating Scale score of 10 and above and/or endorsed
suicide ideation on the CSSRS.
- Depressive symptoms which began or worsened (if already present) during pregnancy or
up to 4 weeks post-partum.
- Able to give informed consent.
- Able to comply with and complete study procedures.
- English speaking.
Exclusion criteria
Post-partum cohort:
- Patients with psychotic symptoms and/or severe cognitive impairment that interfere
with their ability to give informed consent or to complete study assessments.
- Patients who cannot read and write in English as research measures used have only been
validated in English speaking populations.
- Patients that have blood-borne chronic infections including hepatitis B, C, or HIV; as
established at their routine pregnancy blood screens.
- Patients who have any schizophrenia spectrum disorder or bipolar type 1 (based on the
self report and SCID interview).
- Patients who report ongoing substance abuse or dependence (past 3 months).
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials